Using a new treatment to reduce organ damage after severe blood loss
Official title: Recombinant E-NTPDase for shock
Funded at Purine Pharmaceuticals, INC. · NIH-10757117 · Data updated 2026-11-12
This study is testing a new treatment that uses a special enzyme to help protect your body from damage after losing a lot of blood and getting it back quickly, which can happen in emergencies; it aims to see if combining this treatment with IV fluids can reduce inflammation and organ injury, and it could be helpful for patients like you who have experienced severe blood loss.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purine Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Gillette, United States) |
| Project start | September 21, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $299,999 |
| NIH project number | 1R41GM151882-01 |
| Project ID | NIH-10757117 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients who have experienced severe blood loss due to trauma or other medical emergencies.
✕Less likely to help
Patients who are not experiencing hemorrhagic shock or those with conditions unrelated to blood loss may not benefit from this research.
What this research studies
This research investigates a novel treatment using a recombinant enzyme called E-NTPDase to help protect the body from damage caused by low blood volume and subsequent restoration of blood flow, known as hemorrhagic shock. The study aims to assess how this treatment can be combined with intravenous fluids to minimize inflammation and organ injury that often occurs after such traumatic events. By conducting a dose-escalation study, researchers will evaluate the effectiveness of this new therapy in preventing complications associated with ischemia-reperfusion injury. Patients experiencing severe blood loss may benefit from this innovative approach.
Why it matters
Potential benefit: If successful, this research could significantly reduce organ damage and improve recovery outcomes for patients suffering from hemorrhagic shock.
How similar studies have gone: Previous research has shown promise in using E-NTPDases to mitigate organ injury in animal models, suggesting potential for success in human applications.
Where this research is happening
-
Purine Pharmaceuticals, INC.
Gillette, United States Active
Researchers
- Principal investigator: Hasko, George — Purine Pharmaceuticals, INC.
- Study coordinator: Hasko, George
Related research
Other NIH-funded projects on the same topics.
-
Pragmatic midodrine trial to reduce ICU vasopressor use in septic shock
A practical, patient-focused trial tests whether taking oral midodrine can lessen the need for IV vasopressors and shorten ICU stays for people with sepsis-related low blood pressure.
-
Understanding how small heat shock proteins protect our cells
A study from the University of Washington explores how tiny chaperone proteins protect eye and other cells from damage, which could help prevent conditions like cataracts and age-related macular degeneration.
-
A new approach to freeing HIV from brain cells and reducing brain inflammation
A patient-focused approach tests a strategy to flush out hidden HIV in the brain and protect brain health by reducing inflammation.
-
Shock patients: better, faster teamwork to find the cause
A team of clinicians works together to quickly identify the exact cause of a patient’s shock to guide the right treatment.
-
Multi-scale model to improve REBOA use in hemorrhagic shock
A researcher team is building a computer model to better predict how to use REBOA, a device that can control bleeding in the torso, so patients with severe trauma may survive.
-
Phospholipid nanoparticle fluid to replace blood volume and protect organs in severe bleeding
A new, bubble-free fluid made of tiny lipid particles is being developed to quickly restore blood volume and protect organs during severe bleeding when real blood isn’t available.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.